UC San Diego UC San Diego Previously Published Works

Title

Correction to "On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review"

Permalink https://escholarship.org/uc/item/13s8s0t6

Journal ACS Pharmacology & Translational Science, 5(3)

ISSN 2575-9108

Authors

Zeifman, Richard J Singhal, Nikhita Breslow, Leah <u>et al.</u>

Publication Date

2022-03-11

DOI

10.1021/acsptsci.2c00014

Peer reviewed

Correction to "On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review"

Richard J. Zeifman, Nikhita Singhal, Leah Breslow, and Cory R. Weissman*

ACS Pharmacol. Transl. Sci. 2021, 4 (2), 436-451. DOI: 10.1021/acsptsci.1c00024

Cite This: ACS Pharmacol. Transl. Sci. 2022, 5, 176–176		Read Online		
ACCESS	III Metrics & More		E Article Recommendations	

pon further review, we identified two suicidality-related events that were not described in the original manuscript. Both of these events were deemed not attributable to the administration of a psychedelic by the authors of the primary outcome trials. One completed suicide was reported by Griffiths et al. (2016) 11 days following the administration of a very low dose (placebo-like) of psilocybin (1 mg/70 kg psilocybin). Importantly, this individual was not administered an "active" dose of psilocybin during the course of the study.¹ One suicide attempt was reported by Anderson et al. (2020) approximately 2 months after the administration of an active dose of psilocybin (21-25.2 mg/70 kg).² For further details, see the supporting information of the respective manuscripts. Although these events are likely not attributable to psychedelic therapy itself, they point to the importance of closely attending to safety within psychedelic therapy and research.

REFERENCES

(1) Griffiths, R. R.; et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. *J. Psychopharmacol* 2016, *30*, 1181–1197.

(2) Anderson, B. T.; et al. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. *EClinicalMedicine* **2020**, *27*, 100538.

Received: January 28, 2022 Published: February 22, 2022



